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Abstract: Darunavir is currently the most recently approved HIV-1 protease inhibitor. It is 
approved for twice-daily dosing with ritonavir in treatment-experienced patients as young as 
6 years of age and is available in numerous pill strengths. Emergence of darunavir-specific 
mutations is generally slow; therefore it can retain activity against viral strains that are resistant 
to other protease inhibitors, including tipranavir. Darunavir pharmacokinetics, clinical efficacy, 
resistance mutations and pharmacodynamics, and adverse effects are reviewed here. Substantial 
data support its use as a potent, well-tolerated option for salvage therapy in highly treatment-
experienced children and adolescents.
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Introduction
As of  2007, 2 million children under 15 years of age were living with HIV in the 
world, with approximately 370,000 new infections and 270,000 deaths that year.1 
Of the 2.3 million new adult infections in 2007, 45% (over 1 million) were in 
adolescents aged 15 to 24 years of age. In some developing countries, seroprevalence 
of  HIV among adolescent males is higher than 5%, with females 2 to 4 times higher 
still, reflecting the burden of the epidemic borne by girls and women.
Nonetheless, in countries that have the resources and infrastructure to ensure 
consistent access to combination antiretroviral therapy, the trajectory of the epidemic 
has been dramatically altered. For example, in North America, the seroprevalence 
rate among adults was only 0.6% in 2007, and there were estimated to be just 
4400 children living with HIV infection, with fewer than 500 new infections that year 
in those under 15 years of age.1 Despite the low burden of HIV infection in developed 
countries relative to the developing world, the most treatment-experienced children 
and adolescents presently reside and obtain care in regions of the world such as the 
United States (US) and Europe. As therapy is increasingly available worldwide, 
however, the number of treatment-experienced children will correspondingly rise 
globally. For these young patients, there is and will be a chronic and pressing need 
for drugs that are active against HIV strains which are resistant to multiple antiret-
roviral agents.2
Control of HIV infection is accomplished through the use of combination 
antiretroviral therapy.3 There are now six therapeutic classes of medications available, 
as shown in Table 1, although not all are licensed for use in children. Entry inhibitors 
include CCR5 antagonists and fusion inhibitors. The former bind to the human Therapeutics and Clinical Risk Management 2009:5 596
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the process. Nucleoside reverse transcriptase inhibitors 
(NRTIs) are analogues of nucleosides/tides (eg, adenine, 
guanine, cytosine, thiamine) and are competitive antagonists 
of the reverse transcription step from viral RNA to double-
stranded DNA. Non-NRTIs (NNRTIs) similarly inhibit this 
step, but through a noncompetitive antagonism. Integrase 
inhibitors prevent the insertion of proviral DNA into the 
host cell genome. Finally, protease inhibitors (PIs) stop 
cleavage and activation of the viral gag-pol polyprotein by 
the viral protease.
The first PI licensed for adults by the US Food and Drug 
Administration (FDA) in December 1995 was saquinavir 
(Invirase®), ushering in the era of effective combination 
therapy for HIV. Saquinavir was followed shortly thereafter 
by ritonavir (Norivr®) and indinavir (Crixivan®) in March 
1996. There have since been 8 additional PIs brought 
to market, many with overlapping resistance profiles. 
In this article we review darunavir (Prezista™, Tibotec 
Pharmaceuticals), currently the most recently licensed PI. 
We will consider the activity of darunavir against HIV strains 
resistant to many or all other PIs and its role in the manage-
ment of HIV-infected children and adolescents.
Darunavir description 
and approval history
Darunavir is a nonpeptidic inhibitor of HIV-1 and HIV-2 
protease, and like other PIs, it prevents cleavage of the HIV 
polyprotein encoded by the gag-pol region. Darunavir, and 
its structural analogue, amprenavir, both bind to a unique site 
on the wild-type protease enzyme at a rate approximately 
one order of magnitude faster than other protease inhibitors, 
including tipranavir.4 Furthermore, darunavir disassociates 
from the wild type protease at a rate 1000-fold more slowly 
than that of other protease inhibitors, including amprenavir 
and tipranavir. Together, darunavir’s rapid binding and 
slow disassociation confer a binding strength two orders of 
magnitude higher than any other protease inhibitor, which is 
believed to confer potency even against viral strains resistant 
to other PIs.4–6
Darunavir is one of 28 unique or combined-formulation 
antiretroviral drugs currently licensed by the FDA and avail-
able for use by HIV-infected adults. Of these medications, 
19 (68%) are also licensed for use in HIV-infected children and 
adolescents, defined by the US Code of Federal Regulations7 
as less than 16 years of age, although the lower age limit 
for licensed dosing varies by drug, as shown in Table 1. 
Among the agents from new therapeutic classes (maraviroc 
and raltegravir) or the “second-generation” agents in older 
Table 1 Current lower age of FDA-licensure for antiretroviral 
drugs obtained from package inserts
Drug  Lower age for licensed 
prescribing
Nucleoside reverse transcriptase 
inhibitors
  Abacavir (Ziagen®) 3 months
  Didanosine (videx®, videx eC®) 6 months, 6 years
  emtricitabine (emtriva™) 3 months
  Lamivudine (epivir®) 3 months
  Stavudine (Zerit®) 6 months
    Tenofovir disoproxil fumarate  
(viread®)
18 years
  Zidovudine (Retrovir®) 6 weeks (treatment dosing) 
birth (prophylactic dosing)
Nonnucleoside reverse transcriptase 
inhibitors
  efavirenz (Sustiva™) 3 years
  etravirine (intelence™) 16 years
  Nevirapine (viramune®) 15 days
  Combination NRTi and/or NNRTi
  Abacavir + lamivudine (epzicom®) 16 years
    Abacavir + lamivudine + zidovudine 
(Trizivir®)
variable (40 kg)
  Tenfovir + emtricitabine (Truvada®) 18 years
    Tenfovir + emtricitabine + efavirenz 
(Atripla®)
18 years
    Zidovudine + lamivudine (Combivir®) 12 years
Protease inhibitors (Pi)
  Atazanavir (Reyataz™) 6 years
  Darunavir (Prezista®) 6 years
  Fos-amprenavir (Lexiva™) 2 years
  indinavir (Crixivan®) 18 years
  Lopinavir/ritonavir (Kaletra®) 14 days
  Nelfinavir (Viracept®) 2 years
  Ritonavir (Norvir®) 2 years (treatment); variable as 
boosting agent with other Pis
  Saquinavir (invirase®) 16 years
  Tipranavir (Aptivus®) 2 years
entry and fusion inhibitors
  enfuvirtide (Fuzeon™) 6 years
  Maraviroc (Selzentry®) 16 years
integrase inhibitor
  Raltegravir (isentress®) 16 years
membrane receptor CCR5 to prevent binding of virions to 
susceptible cells. They are the only therapeutic agents with a 
human target. Fusion inhibitors disrupt the process by which 
virions inject their contents into the target cell cytoplasm 
by binding to the viral gp41 protein, which is essential to Therapeutics and Clinical Risk Management 2009:5 597
Darunavir in children and adolescents Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
classes (darunavir, tipranavir, and etravirine), only darunavir 
and tipranavir are FDA-licensed for children and adolescents. 
Darunavir was originally licensed on June 23, 2006, and 
the label was modified to include children on December 18, 
2008. In the US it is approved for the treatment of HIV-1 
infection in treatment-naïve and treatment-experienced 
adults and treatment-experienced children over 6 years 
of age. It is not currently licensed for children in Europe, 
although application has been submitted for licensure as 
young as 3 years of age.
Pharmacokinetics
Although the majority of pharmacokinetic information 
for darunavir has been obtained from adults, DELPHI 
(Darunavir EvaLuation in Pediatric HIV-1-Infected treatment-
experienced patients, TMC 114-C212) was an open-label, 
Phase I/II manufacturer-sponsored investigation to determine 
the pharmacokinetics, safety, and efficacy of darunavir 
in children and adolescents.8–10 After 2 weeks of dosing, 
darunavir plasma concentrations were measured to obtain 
pharmacokinetic, safety and efficacy data from 44 children. 
Pharmacokinetic results from DELPHI and from adult studies 
are summarized in Table 2. With the goal of best matching 
adult darunavir exposures measured after dosing with 
darunavir 600 mg plus ritonavir 100 mg twice daily, the final 
pediatric dosing recommendations, shown in Table 3, were 
selected for the 48-week safety and efficacy Part II of the 
DELPHI study (discussed in the Clinical Experience section). 
These are the same weight-based recommendations as 
those included in the FDA-approved package insert.
Food, while slowing the rate of darunavir absorption11 
also increases the overall bioavailability by 30% relative to 
the fasted state, and thus the drug should be given with food; 
however, meal composition is irrelevant.11,12 Metabolism 
is almost exclusively by cytochrome P450 (CYP) 3A4;12 
therefore, darunavir is to be administered with low-dose 
ritonavir, which is a potent CYP3A4 inhibitor12 and raises 
the concentrations of darunavir significantly. Approximately 
80% of darunavir is eliminated in the feces, half of which is 
unchanged parent compound when given with ritonavir.13
On October 21, 2008, the FDA licensed an amended 
once-daily dosing regimen for darunavir in treatment-naïve 
HIV-infected adults. In this population the approved daily 
dose is 800 mg in combination with ritonavir 100 mg. 
Darunavir at this dose was studied as one of several darunavir 
dosing arms vs comparator protease inhibitors in the 
POWER-1 and -2 (Performance Of TMC114/r When evalu-
ated in treatment-Experienced patients with PI Resistance) 
studies14 and as the only darunavir treatment arm vs once 
or twice daily lopinavir/ritonavir in the ARTEMIS trial 
Table 2 Pharmacokinetics of darunavir in children and adults from the US Package insert12 and other references as noted
Observation or parameter (adult patients)   
Protein binding 95%
Bioavailability, absolute
  without ritonavir 37%
  with ritonavir 82%
Bioavailability, relative
  food11 +30%
Tmax
a, hours 2.5–4.0
Terminal half-life, hours 15 (when co-administered with ritonavir)
Clearance, L/h (intravenous dosing with ritonavir) 5.9
volume of distribution, L (intravenous dosing)51 131
effect of hepatic impairment No significant change with moderate impairment (Child-Pugh Class B)
effect of renal impairment No significant change with moderate impairment (creatinine clearance 30–60 mL/min)
Typical darunavir Pooled POweR 1 and 2 DeLPHi
concentrationsb N = 119 adults N = 74 children
AUC0–24, µg⋅h/mLc median (range) 123.3 (67.7–213.0) 127.3 (67.1–230.7)
C0h, µg/mLd median (range) 3.5 (1.3–7.4) 3.9 (1.8–7.8)
aTime to maximum concentration
bObserved after darunavir 600 mg plus ritonavir 100 mg twice daily in adults, and according to dosing in Table 2 in children.
cArea under the time-concentration curve from 0 to 24 hours, calculated as 2*AUC0–12.
dConcentration immediately prior to dosing, ie. trough concentration.Therapeutics and Clinical Risk Management 2009:5 598
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(AntiRetroviral Therapy with TMC114 ExaMined In naïve 
Subjects).15 With once-daily dosing in adults, the AUC of 
87.9 mg⋅h/L and C0 of 2.0 mg/L12 are 71% and 57% of the 
twice-daily adult dose.12 However, there is no experience with 
once-daily dosing of darunavir in children or adolescents, 
and it is not recommended.12
In the US, darunavir is supplied as film-coated tablets in 
strengths of 75, 300, 400, and 600 mg, which are stable at 
room temperature. There is a nonlicensed liquid formulation 
which has been used in clinical research only.
In summary, darunavir is available in numerous dosage 
strengths which make weight-based dosing in children 
feasible, although a liquid formulation is not currently on the 
market. The drug is approved for use in children as young as 
six years of age and the dosing recommendations in Table 3 
approximate the exposures seen in adults who are given 
600 mg in combination with ritonavir 100 mg, both twice 
daily. Once daily dosing has not been studied in children 
and is not currently recommended.
Drug interactions
Darunavir itself is both a substrate and inhibitor of CYP3A4,12 
and is always co-administered with ritonavir. Ritonavir 
interacts with several drug metabolizing enzymes in complex 
and opposing ways. It is a potent inhibitor of CYP3A4, and 
a lesser inhibitor of CYP2D6.12 On the other hand, it is an 
inducer of several cytochromes P450, including 1A2, 2B6, 
2C9, and 2C19, as well as glucuronyl transferase.16 Therefore, 
there is significant potential for drug–drug interactions. 
In general, concomitant medications which are primarily 
metabolized by CYP3A4 or 2D6 will tend to have increased 
concentrations, due to inhibition of these enzymes by the 
combination of darunavir and ritonavir, while medications 
metabolized by other CYP isoforms will have lowered con-
centrations due to induction of metabolism by ritonavir.12 
Darunavir has been studied in combination with other anti-
retroviral agents and many nonantiretroviral drugs, all of 
which are reported in the package insert12 and summarized 
in Table 4. A useful, continuously updated resource for 
interactions involving antiretroviral agents is the HIV Drug 
Interaction website (http://www.hiv-druginteractions.org), 
maintained by the University of Liverpool.
The most significant interactions with other antiretrovirals 
to avoid are lopinavir and saquinavir which lower darunavir 
concentrations. Both darunavir and indinavir concentrations 
are somewhat raised with coadministration, so this 
combination should only be used with caution. Atazanavir, 
efavirenz, etravirine, nevirapine, and tenofovir disoproxil 
fumarate have all been shown to lack a significant interac-
tion with darunavir.
Clinical efficacy
Major clinical trials to establish the efficacy and safety of 
darunavir in patients are summarized in Table 5. Efficacy 
will be discussed here, while safety and tolerability will be 
discussed separately. Published clinical experience with 
darunavir in children and adolescents is limited to a case 
report of successful darunavir-based salvage therapy in a 
single child with multi-drug resistant, perinatally transmitted 
HIV17 and abstracts/posters from the DELPHI study of 
80 PI-experienced children ages 6–17 years with baseline 
viral loads 1000 copies/mL, who received 48 weeks 
of darunavir plus ritonavir plus optimized background 
therapy.8,10 Baseline characteristics of the DELPHI study 
population are shown in Table 6. At 48 weeks, the percent 
of children with 1 log10 drop in viral load from baseline 
was 65% and the percent with 50 copies/mL was 48%. 
In accordance with FDA guidelines, analysis was by intent to 
treat, time to loss of virologic control (ITT-TLOVR), where 
success for a given virologic endpoint is defined only in those 
who did not withdraw, whose regimen was not switched for 
virologic failure, and who had reached the endpoint on two 
consecutive visits, with no subsequent failure before end of 
study.18 All others are considered failures. The mean change 
in CD4+ cell count was +147 cells/mm,3 with analysis by 
ITT-noncompleter equals failure (ITT-NC = F), where 
missing data from individuals due to premature study termi-
nation or missed visits are replaced with baseline values.
These response and adverse effect rates are comparable 
to those observed in adults in the POWER studies.19 
POWER 1 and 2 were Phase IIB studies in different 
geographic regions, which compared the safety and efficacy 
of darunavir/ritonavir (600/100 mg twice daily) or placebo 
plus an optimized background antiretroviral regimen in 
highly treatment-experienced adults, similar to the children 
and adolescents in DELPHI. POWER 3 was an extension of 
POWER 1 and 2 in order to satisfy regulatory requirements; 
Table 3 FDA-licensed darunavir/ritonavir dosing in children and 
adolescents
Weight Dose
(kg) (lbs) (darunavir mg) (ritonavir mg)
20 to 30 44 to 66 375 50
30 to 40 66 to 88 450 60
40 88 600 100Therapeutics and Clinical Risk Management 2009:5 599
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(
i
N
R
)
A
n
t
i
c
o
n
v
u
l
s
a
n
t
s
 
c
a
r
b
a
m
a
z
e
p
i
n
e
 
p
h
e
n
o
b
a
r
b
i
t
a
l
,
 
p
h
e
n
y
t
o
i
n
↑
c
a
r
b
a
m
a
z
e
p
i
n
e
↓
p
h
e
n
y
t
o
i
n
↓
p
h
e
n
o
b
a
r
b
i
t
a
l
↔
d
a
r
u
n
a
v
i
r
N
o
 
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
s
 
w
h
e
n
 
i
n
i
t
i
a
t
i
n
g
 
t
h
e
r
a
p
y
.
 
M
o
n
i
t
o
r
 
a
n
t
i
c
o
n
v
u
l
s
a
n
t
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
a
n
d
 
c
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
,
 
w
i
t
h
 
d
o
s
e
 
t
i
t
r
a
t
i
o
n
 
t
o
 
a
c
h
i
e
v
e
 
d
e
s
i
r
e
d
 
r
e
s
p
o
n
s
e
.
A
n
t
i
d
e
p
r
e
s
s
a
n
t
s
 
 
t
r
a
z
o
d
o
n
e
 
d
e
s
i
p
r
a
m
i
n
e
↑
t
r
a
z
o
d
o
n
e
↑
d
e
s
i
p
r
a
m
i
n
e
N
D
U
s
e
 
w
i
t
h
 
c
a
u
t
i
o
n
 
a
n
d
 
c
o
n
s
i
d
e
r
 
a
 
l
o
w
e
r
 
d
o
s
e
 
o
f
 
t
r
a
z
o
d
o
n
e
 
o
r
 
d
e
s
i
p
r
a
m
i
n
e
.
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
4
 
(
C
o
n
t
i
n
u
e
d
)
D
r
u
g
E
f
f
e
c
t
 
o
n
 
d
r
u
g
E
f
f
e
c
t
 
o
n
 
d
a
r
u
n
a
v
i
r
R
e
c
o
m
m
e
n
d
a
t
i
o
n
A
n
t
i
b
a
c
t
e
r
i
a
l
 
c
l
a
r
i
t
h
r
o
m
y
c
i
n
5
6
↑
c
l
a
r
i
t
h
r
o
m
y
c
i
n
↔
d
a
r
u
n
a
v
i
r
N
o
 
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
 
o
f
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
i
s
 
r
e
q
u
i
r
e
d
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
n
o
r
m
a
l
 
r
e
n
a
l
 
f
u
n
c
t
i
o
n
.
 
F
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
r
e
n
a
l
 
i
m
p
a
i
r
m
e
n
t
,
 
t
h
e
 
f
o
l
l
o
w
i
n
g
 
d
o
s
e
 
a
d
j
u
s
t
m
e
n
t
s
 
s
h
o
u
l
d
 
b
e
 
c
o
n
s
i
d
e
r
e
d
:
 
•
 
 
F
o
r
 
s
u
b
j
e
c
t
s
 
w
i
t
h
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
o
f
 
3
0
–
6
0
 
m
L
/
m
i
n
,
 
t
h
e
 
d
o
s
e
 
o
f
 
c
l
a
r
i
t
h
r
o
m
y
c
i
n
 
s
h
o
u
l
d
 
b
e
 
r
e
d
u
c
e
d
 
b
y
 
5
0
%
.
 
•
 
 
F
o
r
 
s
u
b
j
e
c
t
s
 
w
i
t
h
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
 
o
f
 

3
0
 
m
L
/
m
i
n
,
 
t
h
e
 
d
o
s
e
 
o
f
 
c
l
a
r
i
t
h
r
o
m
y
c
i
n
 
 
s
h
o
u
l
d
 
b
e
 
r
e
d
u
c
e
d
 
b
y
 
7
5
%
.
A
n
t
i
f
u
n
g
a
l
s
 
k
e
t
o
c
o
n
a
z
o
l
e
5
7
 
i
t
r
a
c
o
n
a
z
o
l
e
 
 
v
o
r
i
c
o
n
a
z
o
l
e
↑
k
e
t
o
c
o
n
a
z
o
l
e
↑
d
a
r
u
n
a
v
i
r
↑
i
t
r
a
c
o
n
a
z
o
l
e
 
(
n
o
t
 
s
t
u
d
i
e
d
)
↓
v
o
r
i
c
o
n
a
z
o
l
e
 
(
n
o
t
 
s
t
u
d
i
e
d
)
↑
d
a
r
u
n
a
v
i
r
 
(
k
e
t
o
c
o
n
a
z
o
l
e
 
 
o
r
 
i
t
r
a
c
o
n
a
z
o
l
e
)
w
h
e
n
 
c
o
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
 
i
s
 
r
e
q
u
i
r
e
d
,
 
t
h
e
 
d
a
i
l
y
 
d
o
s
e
 
o
f
 
k
e
t
o
c
o
n
a
z
o
l
e
 
o
r
 
i
t
r
a
c
o
n
a
z
o
l
e
 
s
h
o
u
l
d
 
n
o
t
 
e
x
c
e
e
d
 
2
0
0
 
m
g
.
 
v
o
r
i
c
o
n
a
z
o
l
e
 
s
h
o
u
l
d
 
n
o
t
 
b
e
 
a
d
m
i
n
i
s
t
e
r
e
d
 
t
o
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
d
a
r
u
n
a
v
i
r
/
r
i
t
o
n
a
v
i
r
 
u
n
l
e
s
s
 
a
n
 
a
s
s
e
s
s
m
e
n
t
 
o
f
 
t
h
e
 
b
e
n
e
fi
t
/
r
i
s
k
 
r
a
t
i
o
 
j
u
s
t
i
fi
e
s
 
t
h
e
 
u
s
e
 
o
f
 
v
o
r
i
c
o
n
a
z
o
l
e
.
A
n
t
i
m
y
c
o
b
a
c
t
e
r
i
a
l
 
r
i
f
a
b
u
t
i
n
 
r
i
f
a
m
p
i
n
↑
r
i
f
a
b
u
t
i
n
↑
2
5
-
O
-
d
e
s
a
c
e
t
y
l
r
i
f
a
b
u
t
i
n
N
D
↑
d
a
r
u
n
a
v
i
r
↓
d
a
r
u
n
a
v
i
r
R
e
d
u
c
e
 
d
o
s
e
 
o
f
 
r
i
f
a
b
u
t
i
n
 
b
y
 
a
t
 
l
e
a
s
t
 
7
5
%
 
o
f
 
t
h
e
 
u
s
u
a
l
 
d
o
s
e
 
(
3
0
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
)
 
t
o
 
a
 
m
a
x
i
m
u
m
 
d
o
s
e
 
o
f
 
1
5
0
 
m
g
 
e
v
e
r
y
 
o
t
h
e
r
 
d
a
y
.
 
i
n
c
r
e
a
s
e
d
 
m
o
n
i
t
o
r
i
n
g
 
f
o
r
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
i
s
 
w
a
r
r
a
n
t
e
d
 
i
n
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
t
h
i
s
 
c
o
m
b
i
n
a
t
i
o
n
 
a
n
d
 
f
u
r
t
h
e
r
 
d
o
s
e
 
r
e
d
u
c
t
i
o
n
 
o
f
 
r
i
f
a
b
u
t
i
n
 
m
a
y
 
b
e
 
n
e
c
e
s
s
a
r
y
.
R
i
f
a
m
p
i
n
 
i
s
 
a
 
p
o
t
e
n
t
 
i
n
d
u
c
e
r
 
o
f
 
C
Y
P
4
5
0
 
m
e
t
a
b
o
l
i
s
m
.
 
D
R
v
/
r
 
s
h
o
u
l
d
 
n
o
t
 
b
e
 
u
s
e
d
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
r
i
f
a
m
p
i
n
,
 
a
s
 
t
h
i
s
 
m
a
y
 
c
a
u
s
e
 
s
i
g
n
i
fi
c
a
n
t
 
l
o
s
s
 
o
f
 
t
h
e
r
a
p
e
u
t
i
c
 
e
f
f
e
c
t
 
t
o
 
D
R
v
/
r
.
 
 
T
h
i
s
 
c
o
m
b
i
n
a
t
i
o
n
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
.
β
-
B
l
o
c
k
e
r
s
 
m
e
t
o
p
r
o
l
o
l
 
 
t
i
m
o
l
o
l
↑
b
e
t
a
-
b
l
o
c
k
e
r
s
N
D
C
a
u
t
i
o
n
 
i
s
 
w
a
r
r
a
n
t
e
d
 
a
n
d
 
c
l
i
n
i
c
a
l
 
m
o
n
i
t
o
r
i
n
g
 
o
f
 
p
a
t
i
e
n
t
s
 
i
s
 
r
e
c
o
m
m
e
n
d
e
d
.
 
 
A
 
d
o
s
e
 
d
e
c
r
e
a
s
e
 
m
a
y
 
b
e
 
n
e
e
d
e
d
 
f
o
r
 
t
h
e
s
e
 
d
r
u
g
s
.
B
e
n
z
o
d
i
a
z
e
p
i
n
e
s
 
m
i
d
a
z
o
l
a
m
 
 
t
r
i
a
z
o
l
a
m
↑
m
i
d
a
z
o
l
a
m
↑
t
r
i
a
z
o
l
a
m
N
D
C
o
-
a
d
m
i
n
i
s
t
e
r
 
i
n
 
a
 
s
e
t
t
i
n
g
 
w
h
i
c
h
 
e
n
s
u
r
e
s
 
c
l
o
s
e
 
c
l
i
n
i
-
c
a
l
 
m
o
n
i
t
o
r
i
n
g
 
a
n
d
 
a
p
p
r
o
p
r
i
a
t
e
 
m
e
d
i
c
a
l
 
m
a
n
a
g
e
m
e
n
t
 
i
n
 
c
a
s
e
 
o
f
 
r
e
s
p
i
r
a
t
o
r
y
 
d
e
p
r
e
s
s
i
o
n
 
a
n
d
/
o
r
 
p
r
o
l
o
n
g
e
d
 
s
e
d
a
t
i
o
n
.
 
C
o
n
s
i
d
e
r
 
d
o
s
a
g
e
 
r
e
d
u
c
t
i
o
n
 
f
o
r
 
m
i
d
a
z
o
l
a
m
,
 
e
s
p
e
c
i
a
l
l
y
 
i
f
 
m
o
r
e
 
t
h
a
n
 
a
 
s
i
n
g
l
e
 
d
o
s
e
 
o
f
 
m
i
d
a
z
o
l
a
m
 
i
s
 
a
d
m
i
n
i
s
t
e
r
e
d
.
 
C
o
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
 
o
f
 
o
r
a
l
 
m
i
d
a
z
o
l
a
m
 
o
r
 
t
r
i
a
z
o
l
a
m
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
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C
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
s
 
f
e
l
o
d
i
p
i
n
e
 
n
i
f
e
d
i
p
i
n
e
 
n
i
c
a
r
d
i
p
i
n
e
↑
c
a
l
c
i
u
m
 
c
h
a
n
n
e
l
 
b
l
o
c
k
e
r
s
N
D
U
s
e
 
c
a
u
t
i
o
n
 
a
n
d
 
c
l
i
n
i
c
a
l
 
m
o
n
i
t
o
r
 
p
a
t
i
e
n
t
s
 
f
o
r
 
c
l
i
n
i
c
a
l
 
e
f
f
e
c
t
.
C
o
r
t
i
c
o
s
t
e
r
o
i
d
:
 
 
s
y
s
t
e
m
i
c
 
 
d
e
x
a
m
e
t
h
a
s
o
n
e
N
D
↓
d
a
r
u
n
a
v
i
r
C
h
r
o
n
i
c
,
 
s
y
s
t
e
m
i
c
 
d
e
x
a
m
e
t
h
a
s
o
n
e
 
i
n
d
u
c
e
s
 
C
Y
P
3
A
 
a
n
d
 
c
a
n
 
t
h
e
r
e
b
y
 
d
e
c
r
e
a
s
e
 
d
a
r
u
n
a
v
i
r
 
p
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
.
C
o
r
t
i
c
o
s
t
e
r
o
i
d
:
 
i
n
h
a
l
e
d
/
n
a
s
a
l
 
fl
u
t
i
c
a
s
o
n
e
 
p
r
o
p
i
o
n
a
t
e
↑
fl
u
t
i
c
a
s
o
n
e
 
p
r
o
p
i
o
n
a
t
e
 
(
p
l
a
s
m
a
)
N
D
C
o
n
s
i
d
e
r
 
a
l
t
e
r
n
a
t
i
v
e
s
,
 
p
a
r
t
i
c
u
l
a
r
l
y
 
f
o
r
 
l
o
n
g
 
t
e
r
m
 
u
s
e
.
e
r
g
o
t
 
d
e
r
i
v
a
t
i
v
e
s
 
d
i
h
y
d
r
o
e
r
g
o
t
a
m
i
n
e
 
e
r
g
o
n
o
v
i
n
e
 
e
r
g
o
t
a
m
i
n
e
 
m
e
t
h
y
l
e
r
g
o
n
o
v
i
n
e
↑
e
r
g
o
t
s
N
D
P
o
t
e
n
t
i
a
l
 
f
o
r
 
s
e
r
i
o
u
s
 
a
n
d
/
o
r
 
l
i
f
e
-
t
h
r
e
a
t
e
n
i
n
g
 
e
v
e
n
t
s
 
s
u
c
h
 
a
s
 
a
c
u
t
e
 
e
r
g
o
t
 
t
o
x
i
c
i
t
y
 
c
h
a
r
a
c
t
e
r
i
z
e
d
 
b
y
 
p
e
r
i
p
h
-
e
r
a
l
 
v
a
s
o
s
p
a
s
m
 
a
n
d
 
i
s
c
h
e
m
i
a
 
o
f
 
t
h
e
 
e
x
t
r
e
m
i
t
i
e
s
 
a
n
d
 
o
t
h
e
r
 
t
i
s
s
u
e
s
.
 
C
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
 
D
R
v
/
r
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
.
G
i
 
m
o
t
i
l
i
t
y
 
a
g
e
n
t
 
c
i
s
a
p
r
i
d
e
↑
c
i
s
a
p
r
i
d
e
N
D
T
h
e
r
e
 
i
s
 
a
 
p
o
t
e
n
t
i
a
l
 
f
o
r
 
s
e
r
i
o
u
s
 
a
n
d
/
o
r
 
l
i
f
e
-
t
h
r
e
a
t
e
n
i
n
g
 
r
e
a
c
t
i
o
n
s
 
s
u
c
h
 
a
s
 
c
a
r
d
i
a
c
 
a
r
r
h
y
t
h
m
i
a
s
.
 
T
h
i
s
 
c
o
m
b
i
n
a
t
i
o
n
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
.
H
e
r
b
a
l
 
p
r
o
d
u
c
t
 
S
t
.
 
J
o
h
n
’
s
 
 
w
o
r
t
N
D
↓
d
a
r
u
n
a
v
i
r
D
R
V
/
r
 
t
h
e
r
a
p
e
u
t
i
c
 
e
f
fi
c
a
c
y
 
m
a
y
 
b
e
 
c
o
m
p
r
o
m
i
s
e
d
.
 
T
h
i
s
 
c
o
m
b
i
n
a
t
i
o
n
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
.
H
M
G
-
C
o
A
 
r
e
d
u
c
t
a
s
e
 
i
n
h
i
b
i
t
o
r
s
 
p
r
a
v
a
s
t
a
t
i
n
 
 
a
t
o
r
v
a
s
t
a
t
i
n
 
r
o
s
u
v
a
s
t
a
t
i
n
 
l
o
v
a
s
t
a
t
i
n
 
s
i
m
v
a
s
t
a
t
i
n
↑
p
r
a
v
a
s
t
a
t
i
n
↑
a
t
o
r
v
a
s
t
a
t
i
n
↑
r
o
s
u
v
a
s
t
a
t
i
n
↑
l
o
v
a
s
t
a
t
i
n
↑
s
i
m
v
a
s
t
a
t
i
n
N
D
U
s
e
 
t
h
e
 
l
o
w
e
s
t
 
p
o
s
s
i
b
l
e
 
d
o
s
e
 
o
f
 
a
t
o
r
v
a
s
t
a
t
i
n
,
 
p
r
a
v
a
s
t
a
t
i
n
 
o
r
 
r
o
s
u
v
a
s
t
a
t
i
n
 
w
i
t
h
 
c
a
r
e
f
u
l
 
m
o
n
i
t
o
r
i
n
g
,
 
o
r
 
c
o
n
s
i
d
e
r
 
o
t
h
e
r
 
H
M
G
-
C
o
A
 
r
e
d
u
c
t
a
s
e
 
i
n
h
i
b
i
t
o
r
s
 
s
u
c
h
 
a
s
 
fl
u
v
a
s
t
a
t
i
n
.
U
s
e
 
o
f
 
l
o
v
a
s
t
a
t
i
n
 
o
r
 
s
i
m
v
a
s
t
a
t
i
n
 
w
i
t
h
 
D
R
v
/
r
 
i
s
 
C
O
N
T
R
A
I
N
D
I
C
A
T
E
D
 
d
u
e
 
t
o
 
p
o
t
e
n
t
i
a
l
 
f
o
r
 
m
y
o
p
a
t
h
y
,
 
i
n
c
l
u
d
i
n
g
 
r
h
a
b
d
o
m
y
o
l
y
s
i
s
.
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
 
c
y
c
l
o
s
p
o
r
i
n
e
 
 
t
a
c
r
o
l
i
m
u
s
 
s
i
r
o
l
i
m
u
s
↑
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
N
D
M
o
n
i
t
o
r
 
c
o
n
c
e
n
t
r
a
t
i
o
n
s
 
o
f
 
t
h
e
 
i
m
m
u
n
o
s
u
p
p
r
e
s
s
i
v
e
 
a
g
e
n
t
.
N
a
r
c
o
t
i
c
 
a
n
a
l
g
e
s
i
c
 
m
e
t
h
a
d
o
n
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however, a placebo arm was not included in POWER 3.20 
At week 48, combined analysis of 230 participants from 
POWER 1 and 2 showed a drop of 1 log10 viral copies/mL 
from baseline in 61% of the participants, and 45% of them 
achieved 50 copies/mL19 (compared with 65% and 48% of 
the DELPHI participants). In addition to baseline PI muta-
tions and RAMs, the number of active NRTIs in the back-
ground regimen was strongly associated with 1 log10 drop 
in viral copies/mL: 42% in the darunavir arm vs none in the 
comparator arm reached this endpoint with no active NRTIs 
(P  0.0001); with one active NRTI it was 69% and 13% 
(P  0.0001); and with 2 active NRTIs, it was 68% and 
28% (P = 0.001). The mean CD4+ cell increase in POWER 1 
and 2 was 102 cells/mm3 (compared with 147 in the children 
and adolescents in the DELPHI cohort). Virologic and 
immunologic results were very similar from the additional 
patients in POWER 3, as shown in Table 5.20
Not surprisingly, given the structural similarity to 
amprenavir, a previous history of failure with fos-amprenavir 
was associated with reduced response to darunavir.21 In the 
POWER and DUET studies, average 48-week viral load 
change from baseline was –1.47 log10 (± 0.15) copies/mL in 
73 patients with a history of failure on an amprenavir-based 
regimen vs –1.65 log10 (± 0.06) copies/mL in 450 patients 
regardless of prior amprenavir exposure (P  0.0001, 
T-Test).22 Although this was highly statistically signifi-
cant, it has been argued that the clinical significance of a 
0.3 log10 difference is minimal23 and the percentage of those 
achieving 50 copies/mL in each group at 48 weeks was not 
significantly different (38% vs 45%, P = 0.40, Chi-square).
ARTEMIS was a Phase III, randomized, open-label, 
noninferiority comparison of either darunavir/ritonavir 
(800/100 mg once daily) or lopinavir/ritonavir plus optimized 
background antiretrovirals in treatment-naïve adults.15 
Therefore, the ARTEMIS study population was different 
than the DELPHI and POWER populations by prior treat-
ment experience. Accordingly, virologic response rates were 
higher in ARTEMIS, with 84% of 343 participants in the 
darunavir arm achieving 50 copies/mL at week 48, which 
was not inferior to the lopinavir arm (78% of 346). The 
median changes in CD4+ cell count at week 48 were +137 and 
+141 cells/mm3 for darunavir and lopinavir, respectively.
TITAN (TMC114/r In Treatment-experienced pAtients 
Naïve to lopinavir) was a Phase III, randomized, open 
label companion trial to ARTEMIS, which again compared 
darunavir to lopinavir, but in a treatment-experienced popu-
lation who were naïve to lopinavir, although participants 
did not have to be susceptible to lopinavir at baseline.24 
Participants were randomized 1:1 to either darunavir/ritonavir 
600/100 mg twice daily, or lopinavir/ritonavir 400/100 mg 
twice daily. Both study arms included optimized background 
therapy, but enfuvirtide was excluded. At 48 weeks, 71% of 
the patients in the darunavir arm had 50 viral copies/mL 
by ITT-TLOVR analysis, vs 60% in the lopinavir arm 
(P = 0.005). Similarly, the mean change in viral load from 
baseline was –1.95 vs –1.72 log10 copies/mL in the darunavir 
and lopinavir arms, respectively (P = 0.046). Among 
patients with baseline reduced susceptibility to lopinavir, 
the percentage in each group with 50 viral copies/mL was 
72% vs 28%, highlighting the usefulness of darunavir in the 
setting of baseline lopinavir resistance. The mean change 
in CD4+ cells was not significantly different in the two 
arms: +88 vs +81 cells/µL.
In summary, darunavir has demonstrated virologic and 
immunologic efficacy in highly treatment-experienced 
children and adolescents which closely matches the efficacy 
in treatment-experienced adults. Darunavir has not been 
studied in treatment-naïve children and adolescents, but 
is effective in treatment-naïve adults. Prior failure with 
amprenavir or fos-amprenavir may be associated with slightly 
reduced efficacy, due to structural similarities between 
amprenavir and darunavir.
Pharmacokinetic–
pharmacodynamic predictors 
of darunavir clinical efficacy
Numerous pharmacokinetic and pharmacodynamic factors 
have been studied to predict virologic and immunologic 
responses to darunavir therapy, including baseline darunavir 
susceptibility, darunavir drug concentrations, total number of 
active drugs in the regimen, and inhibitory quotients. These 
are summarized in Table 7 and detailed in the following 
sections.
Susceptibility of HIV isolates to antiretroviral agents at 
baseline prior to starting new therapy or at the time of thera-
peutic failure may be broadly measured using one of two 
techniques: phenotypic or genotypic, with a third technique a 
hybrid of the two known as a virtual phenotype.25 Phenotypic 
susceptibility is reported as the concentration of drug required 
to inhibit laboratory growth of the patient’s dominant viral 
strains by 50% (IC50), or as the fold-change in IC50 relative to 
the IC50 for wild-type virus. A related but not equal parameter 
is the concentration required for 50% of maximal in vivo or 
clinical effect (EC50), which is a benchmark defined through 
clinical testing: against wild-type virus, the protein-corrected Therapeutics and Clinical Risk Management 2009:5 604
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darunavir EC50 is 55 ng/mL.15 Genotypic susceptibility is 
reported as a list of mutations in the patient’s dominant viral 
strains, along with rules-based interpretations, ie,susceptible, 
possibly resistant, or resistant. The virtual phenotype provides 
an estimation of viral IC50 or fold-change in IC50, and is 
calculated using the patient’s genotype, a large database 
of paired viral genotype-phenotype measurements, and 
weighted linear regression techniques.26
Common measures to quantify concentration-effect rela-
tionships include comparisons of total drug exposure (AUC), 
trough drug concentrations, or inhibitory quotients (IQ) in 
virologic responders vs nonresponders. The IQ is calculated 
as the ratio of drug concentration to viral susceptibility to 
that drug.27 Typically, the predose trough concentration is 
the reference drug concentration, while susceptibility may 
be quantified as the fold change in IC50 relative to wild-type 
virus by phenotypic or virtual phenotypic assays (pIQ, vIQ) 
or by the number of resistance associated mutations (RAMs) 
by genotypic assay (gIQ).
Genotypic susceptibility 
and outcomes
Combined analysis28 from the POWER 1, 2 and 3 and DUET 
(etravirine plus placebo or darunavir in treatment-experienced 
patients) studies detected 11 darunavir Resistance Associated 
Mutations (RAMs) in 10 codons, which have been 
adopted in all three of the major HIV resistance databases 
(International AIDS Society-USA [IAS, http://www.iasusa.
org], Stanford [http://hivdb.stanford.edu]., and French 
National Agency for AIDS Research [ANRS, http://www.
hivfrenchresistance.org]). The mutations are V11I, V32I, 
L33F, I47V, I50V, I54L/M, T74P, L76V, I84V and L89V. 
Mutation overlap with other PIs according to IAS is shown in 
Table 8, although mutations for older drugs such as indinavir, 
nelfinavir and saquinavir are likely under-represented due to 
lack of current research.29
The Virco virtual phenotype database contains 82 unique 
mutations or pairs of mutations identified using their linear 
modeling algorithm which increase the fold-change in 
darunavir phenotypic IC50, including all of the 11 darunavir-
specific RAMs.30 However, only four (I54L, T74P, L76V, 
and I84V) of these primary RAMs individually contribute 
more than a 2-fold increase in darunavir IC50 (Virco, Inc., 
data on file). However, there is a relative paucity of primary 
darunavir RAMs in PI-resistant clinical samples submitted 
to Virco,28 suggesting that resistance to darunavir emerges 
slowly, and that darunavir can retain activity against viral 
quasispecies with a high degree of resistance to other PIs.
The number of darunavir RAMs present prior to 
therapy with darunavir is related to the degree of PI 
experience, and influences the success rate of darunavir 
therapy. In the combined POWER cohort, which was highly 
PI-experienced, there was a median of 12 PI RAMs prior to 
initiating therapy with darunavir. Among these PI RAMs, at 
least one was a darunavir RAM in 82% of patients , ranging 
up to 4 darunavir RAMs in 11% of the patients.31 The most 
commonly observed darunavir RAMs were L33F (42%), 
I84V (39%), and I47V (13%), with others ranging between 
5% and10%. The probability of achieving a viral load 
of 50 copies/mL ranged from 65% in those with no base-
line darunavir RAMs, to only 10% in those with 4 RAMs. 
In the PREDZISTA cohort, 89% of those with 4 darunavir 
RAMs achieved 200 copies/mL at 12 weeks, vs none 
with 5 RAMs.32
Table 6 Baseline characteristics of the DeLPHi pediatric cohort
Demographics n (%)
Male 57 (71)
Age
  6 to 12 years 24 (30)
  12 to 17 years 56 (70)
Perinatal infection 62 (78)
CDC class C 40 (50)
Disease characteristics
  Mean (SD) viral load (log10 copies/mL) 4.64 (0.80)
  Median (range) CD4+ cell count (cells/mm3) 330 (6–1505)
  Median (range) CD4+ cell % 17 (1–47)
Previous antiretroviral treatment
  Median (range) number of drugs 9 (3–19)
  1 Pi, n (%) 77 (96)
  1 NNRTi, n (%) 63 (79)
  2 NRTis, n (%) 80 (100)
  enfuvirtide, n (%) 8 (10)
Baseline mutations
  Pi, median (range) number per patient 11 (0–19)
  Major Pi, median (range) number per patient 3 (0–6)
  Patients with darunavir RAMs, n
  0 39
  1 17
  2 15
  3 9
  NNRTi, median (range) number per patient 2 (0–4)
  NRTi, median (range) number per patient 4 (0–8)
Abbreviations: CDC, Centers for Disease Control; NRTi, nucleoside reverse 
transcriptase inhibitors; NNRTi, non-nucleoside reverse transcriptase inhibitors; 
Pi, protease inhibitors; RAMs, resistance associated mutations.Therapeutics and Clinical Risk Management 2009:5 606
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In another, less PI-experienced cohort of 1021 patients 
who were failing PI therapy, and who had a median of 5 PI 
RAMS per patient, there was a lower prevalence of darunavir 
RAMs. I47V, I50V, 54L/M and L89V all had a frequency 
below 2.5%; L33F and I84V had rates of 11% and 14.5%, 
respectively.21 Only 6.7% of the patients had 3 darunavir 
RAMs , and 68% had no darunavir RAMs. In those patients 
with 3 darunavir RAMs the mean number of RAMs 
to all PIs was 12.3 compared with 5.3 in the patients 
with 3 darunavir RAMs (P  0.0001). Together with the 
Table 7 Significant pharmacokinetic and pharmacodynamic predictors of virologic response with darunavir-based therapy
Predictor Outcome Notes
Baseline virtual phenotypic susceptibility
  Susceptible (S)
  (iC50 FC  10)
  Partial susceptibility (P)
  (iC50 FC 10–40)
  Resistant (R)
  (iC50 FC  40)
vL  50 copies/mL
50%
25%
13%
POweR 1, 2, 331
  S: iC50 FC  10
  i: iC50 FC 10–40
  R: iC50 FC  40
vL  200 copies/mL
68%
46%
20%
PReDZiSTA32
Baseline darunavir RAMs
Number
  0
  1
  2
  3
  4
vL  50 copies/mL
65%
50%
40%
20%
10%
POweR 1, 2, 331
Number
  4
  4–5
  5
vL  200 copies/mL
89%
52%
0%
PReDZiSTA32
Identified darunavir RAMs differ from IAS, Stanford and 
ANRS mutations
Activity of background antiretroviral drugs
GSS
  0
  1
  
vL  50 copies/mL
20%
50%
56%
POweR 1, 219
GSS calculated as the sum of each drug’s score: 
0 for resistant by genotype, 1 for susceptible
GSS 
  0 0.5
  1–1.5
  2–3
vL  200 copies/mL 
20%
59%
70%
PReDZiSTA32 
GSS calculated as the sum of each drug’s score: 0 for 
resistant by genotype, 0.5 for possibly resistant, 1 for 
susceptible
inhibitory quotients
viQ
  0.1
  0.1 to 0.4
  0.4 to 1.4
  1.4
∆VL  –1 log10 
32%
61%
80%
84%
POweR 1, 238
viQ
  1.5 
  1.5
vL  50 copies/mL
29%
71%
Darunavir salvage therapy in Pi-experienced adults39
giQ 
  1.8 
  1.8
vL  200 copies/mL 
0% 
55%
PReDZiSTA32
Notes and Abbreviations: iC50, 50% inhibitory concentration in vitro; FC, fold change in iC50 relative to wild-type iC50;   vL, viral load; RAMs, resistance associated mutations; 
GSS, genotypic sensitivity score, which quantifies the activity of the additional antiretroviral drugs in the regimen based on genotype;  vIQ, virtual phenotypic inhibitory quotient, 
which is the ratio of the trough darunavir concentration to the iC50 of the dominant strains as measured by virtual phenotype; giQ, genotypic inhibitory quotient which is the 
ratio of the trough darunavir concentration to the number of darunavir RAMs in the dominant viral strains.Therapeutics and Clinical Risk Management 2009:5 607
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POWER cohort, these data strongly reinforce that a large 
number of PI mutations accumulate prior to the emergence 
of darunavir RAMs.
In addition to an association with virologic efficacy of 
darunavir therapy, the baseline mutation profile has been 
shown to be an important predictor of the mutational pattern 
that emerges with treatment-associated failure of the drug. 
Genotypes were obtained at baseline and at the time of failure 
in a cohort of 25 treatment experienced patients, all of whom 
failed to achieve or maintain virologic suppression while 
receiving darunavir for at least 3 months.33 Those with 1 
baseline darunavir RAM selected 1 additional RAM at the 
time of failure, suggesting sub-optimal adherence was the 
likely cause. Those with 4 baseline RAMs also selected 1 
additional RAM after failure, likely because the dominant 
viral isolate was already largely resistant to darunavir at base-
line. In contrast, two-thirds of the patients with 2 to 3 baseline 
RAMs selected 2 to 5 additional RAMs after failure. Further-
more, among those with viral replication for 24 weeks on 
darunavir, additional RAMs were selected in 93%, vs only 
40% of those who stopped darunavir earlier.
In the much larger POWER cohort, at 24 weeks, overall 
there were 146 (31%) of 458 patients who either rebounded 
or never achieved virologic suppression.31 In these, the most 
common observed mutation was V32I in 35%. This mutation 
is one of the major mutations associated with failure in the 
Stanford resistance database, although IAS does not list it 
as a major mutation.
Prior failure with tipranavir does not seem to substantially 
increase the risk of acquiring darunavir RAMs, consistent 
with the preservation of tipranavir IC50 discussed in the pre-
vious section. In a small cohort of 47 patients, the Stanford-
based mutation score for darunavir did not significantly 
increase (worsen) after failure with tipranavir, compared 
with the score prior to starting tipranavir.34 The authors 
hypothesize that the preservation of darunavir activity after 
failure with tipranavir may be explained by an overlap in 
primary RAMs between darunavir and tipranavir of only 
four mutations: 33F, 47V, 54M and 84V. Conversely, viral 
isolates that are resistant to darunavir can be resistant in vitro 
to all other PIs except tipranavir.12 In clinical studies, patients 
who fail darunavir are more likely to preserve the activity of 
tipranavir than any other PI.33,35
In summary, 11 darunavir RAMs have been identified 
which contribute to therapeutic failure, especially when 3 
are present at baseline, and which emerge with failure of 
darunavir, especially if failing therapy is prolonged more 
than 6 months. A high number of PI RAMs must generally 
accumulate prior to selection of darunavir RAMs, suggesting 
a high genetic barrier that delays emergence of darunavir 
resistance. Failure with darunavir appears to preserve activity 
to tipranavir, if present at baseline. The converse is also true, 
that failure with tipranavir appears to preserve the activity 
of darunavir.
Phenotypic susceptibility 
and outcomes
According to the vircoTYPE HIV-1® virtual phenotypic 
database (Virco, Inc.), there is a 20% loss of clinical activity 
when the in vitro IC50 of the patient’s dominant viral strain 
is increased by 10-fold relative to wild type, and an 80% 
loss of activity when the IC50 is increased by 106.9-fold.36 
For the Phenosense® assay (Monogram, Inc.), the lower 
cutoff is the same, but due to methodologic differences the 
higher cutoff that defines resistance is a 40-fold increase in 
the IC50,37 considerably lower than the vircoTYPE cutoff; 
therefore, resistance results from these two tests are not fully 
interchangeable.
In combined analysis of all three POWER studies, base-
line virtual phenotypic susceptibility was highly predictive 
of the percent of patients with a viral load 50 copies/mL 
at week 48. Relative to wild-type virus, a 10-fold change 
Table 8 Shared darunavir resistance mutations with other protease inhibitors29
DRV V11I V32I L33F I47V I50V I54LM T74P L76V I84V L89V
ATv 21% m m M m M
f-APv 55% m m M m m M
iDv 29% m m m M
LPv 35% M m M m m m
NFv 10% m
SQv 18% m m
TPv 29%     M M   m M   M  
Notes: Major darunavir mutations are in bold. Percentages are the number of shared mutations divided by the total number of resistance mutations for each drug.
Abbreviations: M, major mutation; m, minor mutation;   ATV, atazanavir; f-APV, fosamprenavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; SQV, saquinavir;   TPV, tipranavir.Therapeutics and Clinical Risk Management 2009:5 608
Neely and Kovacs Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in protein-adjusted IC50 was associated with a 50% rate of 
suppression, compared with 25% in the intermediate range 
(10- to 40-fold), and 13% in the resistant range (40-fold).31 
In the PREDZISTA study of 65 PI-experienced patients 
receiving darunavir as a component of salvage therapy, base-
line fold change was also associated with outcome, ranging 
from virologic response in 68% with a fold change 10, 
to only 20% with a fold change 40.32 Baseline resistance 
to darunavir was extremely low in both the ARTEMIS15 
(treatment-naïve) and TITAN24 (moderately treatment-
experienced) studies, precluding any conclusions about 
relationship to the odds of virologic suppression.
Failure with darunavir appears to preserve the phenotypic 
sensitivity of tipranavir, the other nonpeptidic PI, if active at 
baseline. In the POWER cohort, those who failed darunavir 
therapy predictably had a 24-week median darunavir IC50 91.1-
fold higher than wild type IC50, compared to a baseline fold 
change of only 12.6.31 Despite this increase in darunavir 
IC50, the median fold change in tipranavir IC50 was 2.6 at 
24 weeks compared to 3.1 at baseline. Over 80% of isolates 
susceptible to tipranavir at baseline were still susceptible to 
tipranavir after failure with darunavir.
In summary, in large numbers of treatment-experienced 
patients, baseline phenotypic susceptibility was an important 
predictor of virologic suppression after starting darunavir-
based combination antiretroviral therapy. Failure with 
darunavir does not appear to increase the tipranavir IC50, 
suggesting that the drugs have different mutational pathways 
to resistance. This will be discussed more in the next 
section.
Concentrations, inhibitory  
quotients and outcomes
In the POWER 1 and 2 cohorts, there was a statistically 
significant, but weak relationship between darunavir plasma 
AUC (P = 0.026) or trough concentration (P = 0.010) 
and 1 log10 reduction in viral load at week 24 compared with 
baseline.38 Baseline fold-change in darunavir IC50 and vIQ 
were each more strongly associated with the same outcome 
(P  0.001 for both). Among those patients with a vIQ in the 
highest quartile (1.4), 84% had a viral load drop of more 
than 1 log10 at week 24, compared to only 32% of patients 
with a pIQ in the lowest quartile (0.1).
A smaller study in 37 PI-experienced adults also found 
an association between baseline vIQ and response, identi-
fied by viral suppression 50 copies/mL after 48 weeks 
of darunavir plus optimized background therapy.39 By 
Receiver-Operator Curve (ROC) analysis, the vIQ which 
best discriminated responders from nonresponders was 1.5. 
Among responders, 70.8% had a vIQ  1.5, vs only 29.2% 
in nonresponders (P = 0.028). The median decrease in viral 
load from baseline in those with a vIQ  1.5 was 2.5 log10 
copies/mL, compared with only 0.27 log10 copies/mL for 
those with a vIQ  1.5 (P = 0.004). In contrast to the 
POWER cohort, darunavir trough concentration (P = 0.377), 
baseline PI RAMs (P = 0.918), baseline darunavir RAMs 
(P = 0.918), and baseline fold-change in darunavir IC50 
(P = 0.651) were not significantly different in responders vs 
nonresponders.
The above study also examined the relationship between 
gIQ and virologic outcome. By ROC analysis, the gIQ which 
best discriminated responders from nonresponders was 2.4, 
but the percent of responders higher than this threshold was 
not significantly different from the percent of nonresponders 
(71.4% vs 43.8%, P = 0.105). The median decrease in viral 
load from baseline in those with a gIQ  2.4 was 2.5 log10 
copies/mL, compared with 1.6 log10 copies/mL for those 
with a gIQ  2.4 (P = 0.139). However, in the PREDZISTA 
study, a baseline gIQ of  1.8 was predictive of response 
(viral load 200 copies/mL) after 12 weeks of darunavir-
based therapy, with 55% of those with gIQ  1.8 failing to 
respond, vs none with gIQ  1.8 (P  0.001).32
In summary, the antiviral efficacy of darunavir in patients 
is largely driven by susceptibility of the patient’s dominant 
viral strain, whether measured by phenotype or genotype. 
However, incorporation of darunavir plasma concentrations 
in the form of an IQ contributes some additional information 
to prediction of virologic response. A possible vIQ target is 
1.5, while a candidate gIQ is 1.8. These targets may be help-
ful in individual patients, but it is premature to recommend 
determination of the IQ as part of routine care.
Safety and tolerability
Major adverse effects in the DELPHI, POWER, ARTEMIS 
and TITAN trials are summarized in Table 5 and detailed 
here. In the DELPHI cohort, as might be expected in 
chronically ill children, average baseline height and weight 
were both 1.4 standard deviations below the mean of age-
matched healthy children. At week 48, mean z-score had 
increased by 0.1 (P = 0.136) for height and 0.2 (P = 0.003) 
for weight, indicating that the children were growing and 
gaining weight faster than age-matched peers. There were 
only two clinical adverse effects greater than grade 1 and 
judged to be treatment related: diarrhea and rash. Neither 
were treatment limiting. Laboratory abnormalities greater 
than grade 1 included a decreased absolute neutrophil count Therapeutics and Clinical Risk Management 2009:5 609
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(13%), increased pancreatic amylase (11%), increased alanine 
aminotransferase (ALT, 6%) and aspartate aminotransferase 
(AST, 5%), and lipase (4%). Again, none resulted in cessation 
of darunavir. Darunavir significantly reduced fasting triglyc-
eride levels to within the normal range for adults. In contrast, 
total cholesterol, LDL and HDL all increased significantly, 
but remained below normal adult values. Approximately 
half of the children were receiving lopinavir/ritonavir at the 
time of study entry.
In the POWER 1 and 2 studies,19 the rates of adverse events 
higher than control were nausea (darunavir 18%/ control 
13%), nasopharyngitis (14%/11%), upper respiratory infection 
(12%/7%) and herpes simplex (12%/2%). The most common 
treatment-emergent grade 3 and 4 laboratory abnormalities 
in the darunavir group higher than control were increased 
triglycerides (15%/7%), increased pancreatic amylase 
(6%/5%), increased total cholesterol (7%/2%), and increased 
pancreatic lipase (5%/1%). No cases of clinical pancreatitis 
were observed in patients with lipase abnormalities.
In ARTEMIS, darunavir was also associated with 
increases in triglycerides (3%), pancreatic amylase (7%), 
and total cholesterol (13%), but the lipid abnormalities were 
significantly higher in the lopinavir arm (11% and 23% 
for triglycerides and cholesterol) and similar for amylase 
(5%).15 In TITAN, no adverse events Grade 1 that were 
judged to be related to study drug were more common in the 
darunavir arm.24 Laboratory abnormalities Grade 1 and at 
least possibly related to study drug which were more common 
in the darunavir arm included total cholesterol (32%/29%), 
low-density lipoprotein (19%/17%), pancreatic amylase 
(11%/9%), and pancreatic lipase (5%/4%).
The package insert contains additional safety information 
from the combined analysis of more than 3000 patients 
exposed to darunavir, and these are summarized in 
Table 9.12 Adverse reactions noted in all Phase II tests 
with Grade 1 intensity include abdominal pain, acute 
hepatitis, acute pancreatitis, anorexia, asthenia, diabetes 
mellitus, diarrhea, fatigue, headache, hepatic enzyme 
increased, hypercholesterolemia, hyperglycemia, hypertri-
glyceridemia, immune reconstitution syndrome, low density 
lipoprotein increased, nausea, pancreatic enzyme increased, 
rash, Stevens-Johnson Syndrome and vomiting.
In prelicensure testing, 0.5% of patients developed 
hepatitis, and additional postlicensure reports of hepatitis 
have accrued. Most patients had underlying or concomitant 
processes, such as co-infection with hepatitis B or C, which 
predisposed them to hepatitis. Nonetheless, baseline and 
routine monitoring of AST/ALT is recommended, with 
increased frequency in those who are at risk prior to starting 
darunavir. Rashes were noted in 10%, and were typically 
mild to moderate, occurred during the first month of therapy, 
and resolved spontaneously without the need for treatment 
discontinuation. Severe rash, accompanying a systemic 
hypersensitivity reaction with fever and elevated hepatic 
transaminases, occurred in 0.4% of patients, and Stevens-
Johnson was reported in 0.1%. Darunavir does contain a sulfa 
moiety, and thus should be used with caution in patients who 
have a sulfa allergy, although in clinical trials, the incidence 
of rash/hypersensitivity was the same regardless of the history 
of sulfa allergy. There have been reports of increased hemo-
philia A- or B -associated bleeding, in some cases requiring 
additional Factor VIII. Half of the cases did not result in 
discontinuation of the drug, and a causal relationship has not 
been established. Adverse effects common to all PIs, such 
as hyperglycemia, onset or worsening of diabetes mellitus, 
fat redistribution and immune reconstitution syndrome have 
all been reported for darunavir.
Finally, there is a specific warning in the package insert 
regarding use in young children.12 Due to observed toxicity 
and mortality in juvenile rats dosed with darunavir from 
20 mg/kg to 1000 mg/kg up to days 23 to 26 of age, use of 
darunavir in children under 6 years of age is currently not 
recommended, although as mentioned previously, application 
for licensure in patients as young as 3 years of age is currently 
underway in Europe.
In summary, darunavir has a safety profile in children 
older than 6 years of age that is comparable to that observed in 
more than 3000 adults, with the main adverse effects related 
to gastrointestinal symptoms, lipid abnormalities, pancreatic 
enzyme elevations, and probable immune reconstitution 
phenomena. Overall, rates of these adverse events are similar 
to or better than comparator regimens, and no “black box 
warnings” have been identified by the FDA.
Options for salvage therapy 
in children and adolescents
The most recent US Department of Health and Human 
Services guidelines for antiretroviral therapy in children 
and adolescents contain a newly updated section on 
recommended choices for the next antiretroviral regimen for 
treatment failure with evidence of drug resistance.3 As for 
adults, the goal is 50 viral copies/mL plasma, recognizing 
that this is not always possible. The strategy to select the 
salvage regimen is methodical, but becomes increasingly 
difficult as resistance accumulates, particularly in children 
who have fewer licensed therapeutic options than adults. Therapeutics and Clinical Risk Management 2009:5 610
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Table 9 Rates of darunavir adverse events and laboratory abnormalities observed in treatment-experienced adults, Phase iii clinical 
trial (adapted from US Package insert)12
Darunavir/ritonavir  
600/100 mg twice daily +  
optimized background  
N = 298
Lopinavir/ritonavir  
400/100 mg twice daily +   
optimized background  
N = 297
Gastrointestinal disorders
  Abdominal distension 2% 1%
  Abdominal pain 5% 2%
  Diarrhea 12% 18%
  Dyspepsia 2% 1%
  Flatulence 1% 1%
  Nausea 7% 6%
  vomiting 4% 3%
General disorders and administration site conditions
  Asthenia 3% 1%
  Fatigue 1% 1%
Metabolism and nutrition disorders
  Anorexia 1% 2%
  Diabetes mellitus 1% 0%
Musculoskeletal and connective tissue disorders
  Myalgia 1% 1%
Nervous system disorders
  Headache 2% 3%
Psychiatric disorders
    Abnormal dreams 1% 0%
Skin and subcutaneous tissue disorders
  Pruritus 1% 1%
  Rash 6% 3%
Laboratory parameters
    Alanine aminotransferase
    Grade 2 2.5 to 5.0 × ULN 6% 5%
    Grade 3 5.0 to 10.0 × ULN 2% 2%
    Grade 4 10.0 × ULN 1% 2%
  Aspartate aminotransferase
    Grade 2 2.5 to 5.0 × ULN 4% 6%
    Grade 3 5.0 to 10.0 × ULN 2% 2%
    Grade 4 10.0 × ULN 1% 2%
  Alkaline phosphatase
    Grade 2 2.5 to 5.0 × ULN 1% 0%
    Grade 3 5.0 to 10.0 × ULN 1% 1%
    Grade 4 10.0 × ULN 0% 0%
  Hyperbilirubinemia
    Grade 2 1.5 to 2.5 × ULN 0% 1%
    Grade 3 2.5 to 5.0 × ULN 1% 0%
    Grade 4 5.0 × ULN 1% 0%
  Triglycerides
    Grade 2 5.65–8.48 mmol/L
500–750 mg/dL
11% 11%
(Continued)Therapeutics and Clinical Risk Management 2009:5 611
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Optimally, all regimens should contain at least two, but 
preferably three fully active drugs.
For children failing an NNRTI-based regimen, the next 
regimen should be based on a PI. This is because primary 
resistance to either efavirenz or nevirapine (the first genera-
tion NNRTIs) confers resistance to the other drug, via the 
K103N mutation. Currently, the second-generation NNRTI, 
etravirine, which is active against many isolates that are 
resistant to first-generation NNRTIs, is not approved under 
the age of 18. This is likely to change in the near future, 
as Phase 1 testing in children is complete40 and a proposed 
dose of 5.2 mg/kg twice daily will be tested in the currently 
enrolling Phase 2 PIANO (Pediatric trial with Intelence as 
an Active NNRTI Option) study of treatment-experienced 
children and adolescents over the age of 6 years.41
Conversely, failure on a PI-based regimen leaves several 
options for subsequent therapy depending on prior exposure 
and tolerability concerns. These options are NNRTI-based 
therapy, alternative PI-based therapy with ritonavir boosting, 
or NNRTI + boosted PI-based therapy. Finally, in the setting 
of failure with prior exposure to both PIs and NNRTIs, the 
guidelines recommend either a newer ritonavir-boosted PI 
(darunavir or tipranavir), dual-boosted PI combinations 
(lopinavir/ritonavir plus either atazanavir or saquinavir), 
and/or the use of efuvirtide, etravirine, raltegravir, or 
maraviroc.
In these “deep salvage” scenarios, pediatric providers 
can encounter the need for drugs with no FDA-licensure 
in the pediatric population (Table 1), or even no published 
data. In general, newer therapeutic classes or newer drugs 
Table 9 (Continued)
Darunavir/ritonavir  
600/100 mg twice daily +  
optimized background  
N = 298
Lopinavir/ritonavir  
400/100 mg twice daily +   
optimized background  
N = 297
    Grade 3 8.49–13.56 mmol/L
751–1200 mg/dL
7% 9%
    Grade 4 13.56 mmol/L
1200 mg/dL
2% 5%
    Total cholesterol
    Grade 2 6.20–7.77 mmol/L
240–300 mg/dL
24% 19%
    Grade 3 7.77 mmol/L
300 mg/dL
8% 11%
  Low-density lipoprotein cholesterol
    Grade 2 4.13–4.90 mmol/L
160–190 mg/dL
13% 11%
    Grade 3 4.91 mmol/L
191 mg/dL
7% 8%
  elevated glucose levels
    Grade 2 6.95–13.88 mmol/L
126–250 mg/dL
8% 9%
    Grade 3 13.89–27.75 mmol/L
251–500 mg/dL
1% 1%
    Grade 4 27.75 mmol/L
500 mg/dL
1% 0%
  Pancreatic lipase
    Grade 2 1.5 to 3.0 × ULN 2% 4%
    Grade 3 3.0 to 5.0 × ULN 2% 1%
    Grade 4 5.0 × ULN 1% 0%
  Pancreatic amylase
    Grade 2 1.5 to 2.0 × ULN 6% 6%
    Grade 3 2.0 to 5.0 × ULN 6% 3%
    Grade 4 5.0 × ULN 0% 0%
Abbreviations: ULN, upper limit of normal.Therapeutics and Clinical Risk Management 2009:5 612
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Table 10 Comparison between darunavir and tipranavir
  Darunavir Tipranavir
FDA licensure
    Age
  Pediatric
  indication
 
6 years of age 
Treatment-experienced
 
2 years of age  
Treatment-experienced
Available formulations 75, 300, 400 and 600 mg film-coated tablets 250 mg capsules 100 mg/mL solution
Dosing frequency Twice daily Twice daily
Daily pill burden 
(maximum dose)
4 8
Drug interactions +++ (largely due to ritonavir) ++++ (due to tipranavir and ritonavir)
 
Baseline 
    Prior ARv exposure (median number) 
Pi resistance mutation (median number)
48-week efficacy 
    vL  50 copies/mL
  ∆CD4+ cells/mm3
Rate of adverse effects
    Any 
  Serious
DeLPHi, n = 8010 
 
9  
11 
 
48% 
+147 
 
94% 
14%
P1051, n = 11546 
 
7 
13 
 
35% 
+59 
 
94% 
25%
Abbreviations: ARv, antiretroviral; Pi, protease inhibitors;   vL, viral load.
in older classes will be required to treat these patients. Since 
maraviroc and raltegravir are not approved for use under 
the age of 16 years, and dosing information is unavailable 
for either drug in children, treatment with these agents is 
currently best initiated in the context of a clinical trial. 
Etravirine is not yet licensed for those less than 16 years of 
age, and although there is a candidate pediatric dose, safety 
and efficacy of this dose have not yet been established.
In the guidelines,3 lopinavir/ritonavir is currently listed as 
a preferred agent for initial therapy in children, and therefore 
would be the preferred agent for salvage therapy after failure 
with NNRTIs or perhaps another PI such as nelfinavir. It has 
been shown to be safe, effective, and durable in children 
and adolescents in this setting.42,43 Fos-amprenavir/ritonavir 
has been shown to be noninferior to lopinavir/ritonavir in 
the treatment of treatment-naïve adults,44 and to have good 
long-term virologic suppression in a noncomparative study 
of treatment-experienced adults,45 but it has not been studied 
for salvage therapy in children.
Tipranavir has been studied in treatment-experienced 
children and is the drug most likely to be considered against 
darunavir for deep salvage therapy due to the largely non-
overlapping resistance profiles (see section on Resistance 
Mutations above). Table 10 summarizes the comparison 
between darunavir and tipranavir, which is detailed here. 
The Pediatric AIDS Clinical Trials Group (PACTG), now the 
International Maternal Pediatric Adolescent AIDS Clinical 
Trials (IMPAACT) group co-sponsored the P1051 study 
with the manufacturer to evaluate the safety, tolerability and 
efficacy of tipranavir in treatment-naïve and -experienced 
children aged 2 to 18 years, although 97% of the enrollees 
were treatment-experienced.46 Baseline characteristics of 
the P1051 study population (n = 115) were similar to the 
DELPHI participants, with a median of 7 antiretroviral 
drugs used previously and 13 PI mutations per patient. There 
were two doses studied, the higher of which was tipranavir 
375 mg/m2 plus ritonavir 150 mg/m2 twice daily (n = 57), 
and was the dose that was eventually licensed by the FDA. 
In that group, 35.1% had a viral load of 50 copies/mL 
at 48 weeks and a median change in CD4+ cell count of 
+59 cells/mm3. A high percentage of children in the high-
dose cohort experienced adverse effects, the most common 
being vomiting (42%), cough (30%), diarrhea (26%), pyrexia 
(21%), nausea (18%), nasopharyngitis (12%) and headache 
(11%). Overall, 60% of the high-dose participants had an 
adverse effect judged to be related to the study drug in some 
way, and 7% stopped the drug due to the adverse effect. 
Grade 3 elevations in ALT occurred in 6%; bleeding occurred 
in 14% of those receiving capsules; there were no reported 
Grade 3 or higher elevations in triglycerides.
The overall proportion of patients with a serious adverse 
event was 25%, and this was marginally significantly higher Therapeutics and Clinical Risk Management 2009:5 613
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than in the DELPHI study,10 where the rate was 14% 
(P = 0.05, Chi square). The proportions of patients in the 
DELPHI and P1051 studies with any adverse event were 
the same: 94% vs 94%.
In summary, then, how does tipranavir compare with 
darunavir? Both are dosed with ritonavir, and both are 
administered twice daily. Tipranavir has tablet and liquid 
formulations, while darunavir is only supplied as tablets. 
Although the dosing frequency of each is the same, the pill 
burden for the full adolescent dose is lower for darunavir/
ritonavir, with 2 tablets twice daily, vs 4 tablets twice daily 
for tipranavir/ritonavir. Darunavir is licensed for children 
as young as 6 years of age, while tipranavir is licensed for 
those as young as 2 years of age. Efficacy rates are similar, 
or slightly higher for darunavir. The rate of serious adverse 
effects in the DELPHI study for darunavir was less than 
in the P1051 study for tipranavir, but the overall rate of 
adverse events, without regard to cause, was the same for 
the two drugs. Drug interaction potential for both drugs is 
high, but somewhat higher for tipranavir due to its ability 
to broadly induce and inhibit the activity of numerous drug 
metabolizing enzymes.47 In our clinic, which provides care 
to over 100 HIV-infected children and adolescents, we prefer 
to use darunavir before tipranavir due to darunavir’s lower 
overall pill burden, lower ritonavir dose, and more predict-
able drug interactions; however, available evidence does not 
distinguish a preferred order of sequencing darunavir and 
tipranavir based on efficacy.
Conclusions/recommendations
Darunavir offers a safe and potent new choice of therapy to 
clinicians who care for HIV-infected children and adolescents. 
Because it has not been studied in treatment-naïve children, 
and there are numerous other first-line agents, and because 
laboratory evidence indicates that isolates which become 
resistant to darunavir can be resistant to all other PIs except 
tipranavir, use of darunavir should be restricted to salvage 
therapy. In this role it has activity against isolates which are 
highly resistant to other PIs. There are consistent genotypic 
and phenotypic predictors of virologic response to darunavir 
therapy to aid clinicians in evaluating the likelihood of 
success prior to initiating therapy. Additionally, there are less 
extensive data supporting phenotypic or genotypic inhibitory 
quotients which could be used to adjust therapy in selected 
patients if necessary.
Currently, the most likely pediatric population for whom 
darunavir would be useful is those who were infected with 
HIV at or near the time of birth and who have developed 
substantial antiretroviral drug resistance as they have 
matured. Transmission of multi-drug resistant HIV from 
mother to child is thus far very rare, and limited to case 
reports.17,48,49 Adolescents who are infected through sexual 
contact or intravenous drug abuse generally will mature into 
adulthood before they have sufficient antiretroviral exposure 
to accumulate large numbers of resistance mutations which 
would warrant darunavir therapy.
Therapy for perinatally infected adolescents with 
multi-drug resistant virus remains extremely challenging due 
to adherence and other psychosocial issues.3,50 Nonetheless, 
for selected children and adolescents who have likely 
already failed NNRTI-based therapy, and regimens based 
on atazanavir and lopinavir, darunavir with ritonavir offers 
a well tolerated, potent combination, with a relatively low 
pill burden, and which can have a substantial chance of 
virologic and immunologic benefit even with few additional 
active agents.
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